Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis Posted on March 13, 2024September 26, 2024 by KBD Admin
Applied Therapeutics Announces $100 Million Private Placement Posted on February 28, 2024September 26, 2024 by KBD Admin
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock Posted on February 7, 2024September 26, 2024 by KBD Admin
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement Posted on February 5, 2024September 26, 2024 by Kate Schykerynec
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing Posted on February 5, 2024September 26, 2024 by Kate Schykerynec
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors Posted on January 29, 2024September 26, 2024 by KBD Admin
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock Posted on January 19, 2024September 26, 2024 by KBD Admin
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older Posted on December 15, 2023September 26, 2024 by Kate Schykerynec
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche Posted on December 3, 2023September 26, 2024 by KBD Admin
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn Posted on November 28, 2023December 5, 2023 by KBD Admin
